Factores pronósticos en pacientes con cáncer de mama y metástasis cerebral como primer sitio de recurrencia

Mohar‐Betancourt, Alejandro; Alvarado‐Miranda, Alberto; Torres-Domínguez, Juan Alejandro; Cabrera, Paula; Lara‐Medina, Fernando; Villarreal-Gómez, Yaudim Sadid; Reynoso-Noverón, Nancy

doi:10.21149/9082

Cited by 5 publications

(3 citation statements)

References 28 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have shown that a large tumor burden ( 17 , 18 ), axillary lymph involvement, high tumor number ( 18 , 19 ), high histological grade ( 17 ), triple-negative breast cancer ( 18 , 20 ), high Ki67 index ( 21 ), BRCA1 mutation ( 22 ) and breast cancer metastasis to the CNS ( 20 ) are associated with reduced survival time in breast cancer. The present case was consistent with these findings, although the BRCA gene was not tested for in this case.…”

Section: Discussionmentioning

confidence: 99%

Carcinoma with signet ring cell differentiation associated with invasive breast cancer: A case report

et al. 2023

View full text Add to dashboard Cite

Carcinoma with signet ring cell differentiation is uncommon in patients with invasive breast cancer. Clinical evidence has suggested that the prognosis of this tumor is usually poor if the stage is advanced. The case of a 40-year-old female patient with primary cancer in the right breast accompanied by bilateral neck, axillary, right subclavian and mediastinal lymph node metastases, and left breast metastasis is presented in the current study. The patient developed superior vena cava syndrome and was restricted in lifting the upper right limb when presenting at the Third Affiliated Hospital of Shenzhen University, Shenzhen. The histopathological and immunohistochemical features included ~80% of the tumor cell area having a signet ring cell pattern, exhibiting the phenotype of lobular carcinoma, and ~20% of the tumor cell area exhibiting a ductal carcinoma immunophenotype with neuroendocrine expression The patient received chemotherapy with paclitaxel liposomes and doxorubicin hydrochloride liposomes according to the general guidelines for the treatment of stage IV breast carcinoma. The patient achieved a partial response after 4 cycles of treatment, and then experienced progressive disease in the form of brain metastasis after 6 cycles. Owing to the rarity of carcinoma with signet ring cell differentiation in invasive breast carcinoma, this case report discusses the patient's clinical and histopathological characteristics, and the treatment prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Carcinoma with signet ring cell differentiation associated with invasive breast cancer: A case report

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Breast cancer continues to be the leading cause of cancer death in women in the world, mainly in emerging economies such as Mexico. In this regard, various authors have analyzed and measured the presence of autoantibodies in various types of cancer (including breast cancer), and some have even evaluated the effectiveness for the recognition of breast cancer antigens [3,4]. Even though their concentration and variety differ significantly among subjects, the fact that autoantibodies' individual patterns remain relatively stable throughout life but shift when the individuals begin developing a disease or if they become ill led us to think that they may be used as biomarkers [4,5].…”

Section: Discussionmentioning

confidence: 99%

“…Given the relatively high morbidity and mortality rates associated with BC, public health systems around the world have implemented programs to increase the life expectancy of women, based on timely diagnosis after periodic physical examination of the breasts, image-based screening, and identification of blood molecular markers. Unfortunately, this strategy has been insufficient in decreasing BC morbidity and mortality, especially in countries with developing economies, where population-wide medical mentoring and education is deficient, and the population has limited access to screening programs and treatments [3].…”

Section: Introductionmentioning

confidence: 99%

Autoantibody Diversity Is Augmented in Women with Breast Cancer and Is Related to the Stage of the Disease

Pérez-Hernández,

León-Díaz,

Zentella

et al. 2023

Current Oncology

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequent malignant neoplasia and leading cause of cancer mortality for women. A timely diagnosis of BC is crucial to ensure the best chances of survival. Among the various screening tools for BC, antibodies directed towards self-antigens or tumor-associated antigens (autoantibodies) have emerged as an alternative to image-based screening modalities. However, little attention has been paid to the global diversity of autoantibodies. This work aimed to analyze the diversity of autoantibodies reactive to antigens expressed by the BC cell line T47D in the sera of Mexican women with BC, benign breast pathology (BBP), or without breast pathology (WBP). We found that the diversity of antibodies in the sera was higher in the BC and BBP groups than in the WBP group. Likewise, the diversity changed with the progression of BC. Our results show and measure the complexity of the antibody response in breast health and disease.

show abstract

Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms

Cacho-Díaz

Salmerón-Moreno

Alvarez-Alvarez

et al. 2020

Cancer

View full text Add to dashboard Cite

Background The current study was performed to identify factors that are present at the time of breast cancer (BC) diagnosis that are associated with a higher rate of central nervous system metastasis (CNSm). Methods The authors analyzed a database of patients with a confirmed diagnosis of BC who were referred for a neuro‐oncology consultation at the National Cancer Institute in Mexico City, Mexico, from June 2009 to June 2017. Information was collected prospectively and included demographic, pathologic, and clinical data at the time of diagnosis of BC. Bivariate and multivariate logistic regression models were built to estimate the associations between the development of CNSm and the time after BC diagnosis. Results Among 970 patients with BC, 263 (27%) were diagnosed with CNSm. The median time from BC diagnosis to the development of CNSm was 33 months (interquartile range, 15‐76 months). After multivariate analysis, age <50 years at the time of BC diagnosis (odds ratio [OR], 2.5; 95% confidence interval [95% CI], 1.8‐3.5 [P < .0001]), human epidermal growth factor receptor 2 (HER2)–positive status (HER2+) (OR, 3.6; 95% CI, 2.1‐6.1 [P < .0001]), luminal B/HER2+ subtype (OR, 3.1; 95% CI, 1.9‐5.3 [P < .001]), triple‐negative subtype(OR, 2.4; 95% CI, 1.5‐4 [P = .001]), and Karnofsky performance status ≤70 (OR, 6.6; 95% CI, 4.5‐9.6 [P < .0001]) were associated with a higher frequency of CNSm. Brain parenchyma was the most common site of CNSm. The median overall survival after a diagnosis of CNSm was 12.2 months (95% CI, 9.3‐15.1 months). Conclusions CNSm is not uncommon among patients with BC, particularly in those with neurologic symptoms who require neuro‐oncology evaluation and are aged <50 years at the time of diagnosis, have HER2+ or triple‐negative subtypes, have a poor Karnofsky performance status, and/or have ≥2 non‐CNS metastases.

show abstract

Factores pronósticos en pacientes con cáncer de mama y metástasis cerebral como primer sitio de recurrencia

Cited by 5 publications

References 28 publications

Carcinoma with signet ring cell differentiation associated with invasive breast cancer: A case report

Carcinoma with signet ring cell differentiation associated with invasive breast cancer: A case report

Autoantibody Diversity Is Augmented in Women with Breast Cancer and Is Related to the Stage of the Disease

Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms

Contact Info

Product

Resources

About